Mizuho Maintains Outperform on Minimed Group, Raises Price Target to $26
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Anthony Petrone maintains Minimed Group (NASDAQ:MMED) with a Outperform and raises the price target from $21 to $26.
Mizuho analyst Anthony Petrone maintains Minimed Group (NASDAQ:MMED) with a Outperform and raises the price target from $21 to $26.